Antibodies Industry Data Book Covers Antibodies Production, Research Antibody, Monoclonal & Cancer Monoclonal Antibody, Mammalian IgG Polyclonal Antibody Markets.
Grand View Research’s Antibodies Industry data book is a collection of market sizing & forecast insights, market dynamics & trends, opportunity assessment, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analysis studies. Within the purview of the databook, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.
Antibody Production Market Insights
The global antibody production market size was valued at USD 7.4 billion in 2016 and is projected to grow at 13.5% over the forecast period.
On the basis of type, the antibody production market is segmented into polyclonal antibodies and monoclonal antibodies. In 2016, the monoclonal antibody segment was the highest revenue-generating segment of the market, due to increasing investment in monoclonal antibody research and a large number of antibody-based product launches.
The downstream processing segment is reported to have the largest revenue share of the antibody production industry in 2016 and is projected to grow at the highest CAGR during the forecast period. This procedure involves the use of highly sophisticated, accurate, and efficient products including chromatography instruments & resins.
On the basis of end-use, the antibody production industry is segmented into pharmaceutical & biotechnology companies, research laboratories, and others. The pharmaceutical & biotechnology companies are reported to have the largest revenue share of the market in 2016.
The research laboratories was the second-highest revenue-generating segment of the market, owing to increasing investment in antibody-based research and drug discovery. This segment is expected to grow at a significant CAGR during the forecast period.
Monoclonal Antibodies Market Insights
The global monoclonal antibodies market size was valued at USD 210.06 billion in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 11.04% from 2023 to 2030.
The human source type held the largest share and accounted for 54.3% of the market value in 2022. Human mAbs offer efficient modulation in effector functions and are less immunogenic as compared to chimeric or humanized mAbs.
IIn vitro production type held the larger market share of 76.9% in 2022 due to its economic viability in long production runs and lower propensity for contamination with foreign antigens. In addition, the availability of serum-free culture media and semi-permeable membrane-based systems has increased the feasibility of biomanufacturing operations and is likely to accelerate segment growth.
Oncology segment dominated the applications market for mAbs and accounted for 49.2% of the market value in 2022. This can be attributed to the high number of regulatory approvals for mAbs aimed at cancer treatment. The surge in the incidence of cancer is a key factor anticipated to drive the growth of mAbs therapeutics as these can have minimal adverse effects as compared to other drugs and chemotherapy interventions.
The hospitals segment held the largest market share of 39.7% in 2022 due to the increasing adoption of mAbs for cancer treatment at hospitals. Rising healthcare expenditure across the world, increasing patient awareness levels, and availability of advanced hospital infrastructure in developed countries are factors expected to result in the dominance of the segment during the forecast period.
Access the Global Antibodies Industry Data Book, 2022 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competition benchmarking, macro-environmental analyses, and regulatory & technological framework studies
Cancer Monoclonal Antibodies Market Insights
The global cancer monoclonal antibodies market size was valued at USD 73.79 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 18.20% from 2023 to 2030.
The humanized segment held the highest market share of 40.58% in 2022. Humanized monoclonal antibodies are engineered to replace the mouse-related immunogenic or epitope structures. Due to the low cost, availability, and quick production time for mouse monoclonal antibodies, the humanization of mouse monoclonal antibodies has been applied on a large scale, thereby driving the growth of the market.
The blood cancer segment held the highest market share of 23.94% in 2022. There has been a tremendous increase in demand for hematological disorder treatments over the last three years, which has led pharmaceutical industries to develop novel medications, including cancer monoclonal antibodies. For instance, in August 2020, the FDA approved GSK’s BLENREP for treating patients with refractory or relapsed multiple myeloma.
The hospitals segment held the highest market share of 40.14% in 2022. Some of the factors that can be attributed to the segmental share include the rising prevalence of cancer along with an upsurge in the number of patient hospitalizations. In addition, the availability of innovative drug therapies in hospitals drives patient preference.
Research Antibodies Market Insights
The global research antibodies market size was valued at USD 1.41 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.93% from 2022 to 2030.
The primary antibodies segment captured the largest revenue share of over 75.0% in 2021 and is also projected to grow at the fastest rate throughout the forecast period. This can be attributed to the increasing availability of primary antibodies using rabbits, mice, goats, and other species as hosts and the wide range of utility offered by such antibodies for applications in the R&D space.
The monoclonal antibodies segment accounted for a dominant share of over 60.0% in 2021 due to a sharp increase in the number of cancer research projects that demand high specificity antibodies. As monoclonal antibodies can efficiently adhere to or block antigens on cancer cells, these are employed in the identification and development of new medicines for various cancer types. This factor is expected to expand the growth prospects for the segment in the near future.
The western blotting segment accounted for a dominant share of over 25.0% in 2021 due to the widespread availability and adoption of the technique. In addition, due to the increased accuracy that the western blotting technique offers, it is typically chosen over alternative technologies for applications involving the detection of important protein entities. These attributes are expected to positively affect the segment growth.
In 2021, the rabbit segment held the largest share of over 45.0%. Rabbits are extensively used for antibody production owing to several advantages such as higher affinity antibodies provided by rabbits as compared to those obtained from other animal hosts.
The oncology segment accounted for the largest share of over 30.0% in 2021 owing to a rise in the prevalence of cancer in key geographies. According to the American Cancer Society, in 2021, over 1.9 million new cancer cases were recorded in the U.S. Additionally, over 608,570 cancer deaths were also recorded in the same year in the U.S. As a result, more research antibodies will likely be used for designing and evaluating of new diagnostic and therapeutic approaches for the mitigation of cancer.
The academic and research institutions segment captured the largest revenue share of over 60.0% in 2021 and is projected to grow at the fastest rate throughout the forecast period. This can be attributed to the increase in scientific initiatives by such centers for the development of novel therapies and tests for chronic diseases.
Mammalian Polyclonal IgG Antibody Market Insights
The global mammalian polyclonal IgG antibody market size was valued at USD 1.13 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 5.01% from 2023 to 2030.
The mouse segment is anticipated to exhibit the fastest CAGR of 8.59% from 2023 to 2030 owing to the predominant use of these animals for polyclonal antibody production. Mice’s immune system is similar to the human immune system, their functions of all the genes and the development of egg and sperm are in the same way as a human.
The metabolic biomarkers segment dominated the industry in 2022 and accounted for the largest share of 25.6% of the overall revenue. The increasing use of metabolic biomarkers for the diagnosis of diabetes is anticipated to propel segment growth.
The ELISA segment is anticipated to register the highest CAGR of 7.48% over the forecast years due to its predominant use in antibody-related tests. It is the most often used test due to its accurate diagnosis of diseases, such as AIDS, Lyme disease, syphilis, pernicious anemia, and viral infections.
The pharmaceutical and biotech companies segment is the major contributor to the industry and accounted for the maximum share of more than 34.15% of the overall revenue in 2022. The global pandemic can be a key driver for companies, as discovering an antibody for the coronavirus gives an upper hand to the company in leading the industry.
Antibodies Market – Global Industry Segmentation
Antibody Production Market - Segment Analysis, By Type
- Polyclonal Antibody
- Monoclonal Antibody
- Murine
- Chimeric
- Humanized
Antibody Production - Segment Analysis, By Process
- Upstream processing
- Bioreactors
- Largescale bioreactors
- Single-use bioreactors
- Consumables
- Media
- Buffers and reagents
- Bioreactors
- Downstream processing
- Chromatography systems
- Chromatography resins
- Filtration
- Filtration systems
- Filtration consumables and accessories
Antibody Production Market - Segment Analysis, By End-use
- Pharmaceutical and biotechnology companies
- Research laboratories
- Others
Monoclonal Antibodies Market - Segment Analysis, By Type
- Murine
- Chimeric
- Humanized
- Human
Monoclonal Antibodies Market - Segment Analysis, By Production Type
- In Vivo
- In Vitro
Monoclonal Antibodies Market - Segment Analysis, By Application
- Oncology
- Blood Cancer
- Breast Cancer
- Lung Cancer
- Melanoma
- Colorectal Cancer
- Liver Cancer
- Others
- Autoimmune Diseases
- Infectious Diseases
- Neurological Diseases
- Others
Research Antibodies Market - Segment Analysis, By Product
- Primary
- Secondary
Research Antibodies Market - Segment Analysis, By Type
- Monoclonal Antibodies
- Polyclonal Antibodies
Research Antibodies Market - Segment Analysis, By Technology
- Immunohistochemistry
- Immunofluorescence
- Western Blotting
- Flow Cytometry
- Immunoprecipitation
- ELISA
- Others
Research Antibodies Market - Segment Analysis, By Source
- Mouse
- Rabbit
- Goat
- Other Sources
Research Antibodies Market - Segment Analysis, By Application
- Infectious Diseases
- Immunology
- Oncology
- Stem Cells
- Neurobiology
- Others
Research Antibodies Market - Segment Analysis, By End-use
- Academic & Research Institutes
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
Mammalian Polyclonal IgG Antibody Market - Segment Analysis, By End-use
- Goat
- Rabbit
- Horse
- Mouse
- Others
Mammalian Polyclonal IgG Antibody Market - Segment Analysis, By End-use
- Cardiac Markers
- Metabolic Markers
- Renal Markers
- Others
Mammalian Polyclonal IgG Antibody Market - Segment Analysis, By End-use
- ELISA
- Immunoturbidometry
- Immunoelectrophoresis
- Antibody Identification
- Immunohistochemistry
- Immunocytochemistry
- Western Blotting
Order your copy of the Free Sample of “Antibodies Industry Data Book - Antibodies Production, Research Antibody, Monoclonal & Cancer Monoclonal Antibody, Mammalian IgG Polyclonal Antibody Market Size, Share, Trends Analysis, And Segment Forecasts, 2022 - 2030” Data Book, published by Grand View Research
Antibodies Industry Data Book Regional Outlook
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- APAC
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- MEA
- South Africa
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Antibodies Industry Data Book Competitive Landscape
Competitive rivalry in the Antibody industry is high due to the presence of a large number of both well-established players and small- to mid-sized companies as well as CROs in the market space.
Key players operating in the antibodies industry are –
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Sartorius AG
- GE Healthcare
- Eppendorf AG
- Merck KGaA
- Amgen Inc
- Novartis AG
- AstraZeneca plc
- Abcam plc
- F. Hoffman-La Roche Ltd.
- Eli Lilly
Go through the table of content of Antibodies Industry Data Book to get a better understanding of the Coverage & Scope of the study
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com/sector-reports-list
